$2.46
-0.07-2.77%
最終更新: Oct 16, 4:37 PM
$2.42
-0.11-4.35%
Benzinga
Benzinga
Benzinga
日曜日, 10 18
Benzinga
© 2026 Benzinga | All Rights Reserved
Seres Therapeutics (MCRB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-2.16 | $-1.85 | $-1.92 | $0.78 |
| Actual | $0.47 | $-2.08 | $-1.76 | $0.94 |
| Surprise | +121.8% | -12.4% | +8.33% | +20.5% |
| Revenue | ||||
| Estimate | $179000 | — | $5.9M | $5.9M |
| Actual | $736000 | $358000 | $438000 | $351000 |
| Surprise | +311.2% | — | -92.5% | -94.0% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-1.07 | $-1.09 |
| Revenue | ||
| Consensus | $5.1M | $5.1M |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.47 | $-2.16 | 121.8 % |
| Q1 | May 5, 2026 | $-2.08 | $-1.85 | -12.4 % |
| Q4 | Mar 12, 2026 | $-1.76 | $-1.92 | 8.33 % |
| Q3 | Nov 5, 2025 | $0.94 | $0.78 | 20.5 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $736.00K | $179.00K | 311.2 % |
| Q4 | Mar 12, 2026 | $438.00K | $5.88M | -92.5 % |
| Q3 | Nov 5, 2025 | $351.00K | $5.88M | -94.0 % |
| Q1 | May 7, 2025 | $0 | $16.67M | -100.0 % |